A non-inferiority randomized controlled trial comparing nebulized fentanyl and intravenous morphine for acute pain management in the emergency department.
- 1Department of Emergency Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, 10300, Thailand.
- 2Department of Emergency Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, 10300, Thailand. [email protected].
- 3Department of Nursing, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, 10300, Thailand.
Abstract
Introduction
Intravenous (IV) morphine is the standard treatment for acute pain in emergency department (ED), but is limited by invasiveness and adverse effects. Nebulized fentanyl is a noninvasive alternative. This study aimed to assess the efficacy of nebulized fentanyl compared with IV morphine for acute pain relief 15 min after administration. Secondary outcomes included pain score trends, adverse effects, and rescue analgesia requirements at 30, 45, and 60 min.Methods
We conducted a double-blind, randomized controlled trial in patients aged 18 to 65 years who had severe pain (numeric rating scale(NRS) score ≥ 7) originating from headaches, musculoskeletal conditions, or cancer. Patients with abdominal pain, unstable vital signs, and chronic opioid use were excluded. Participants were randomly assigned to received either nebulized fentanyl (4 mcg/kg) or IV morphine (0.1 mg/kg). Pain scores, adverse events, and rescue analgesia were recorded at 15, 30, 45, and 60 min by emergency medicine residents who were blinded to treatment allocation. Non-inferiority margin was established if the upper limit of the 95% confidence interval (CI) for the mean NRS difference did not exceed 3 points.Results
Seventy-two patients were enrolled, with comparable baseline characteristics and NRS scores (nebulized fentanyl: 7.94 ± 1.09; IV: 8.14 ± 0.90). Both groups showed significant pain reduction at 15 min (nebulized fentanyl: 5.56 ± 1.66; IV: 5.67 ± 1.85; p < 0.001), with no significant difference in mean NRS reduction (p = 0.83). At all measured time points (15, 30, 45, and 60 minutes), the upper limit of the 95% confidence interval (CI) for the mean difference in pain reduction remained below the predefined non-inferiority margin of 3.Conclusions
Nebulized fentanyl is a non-inferior, non-invasive alternative to IV morphine for severe acute pain in the ED. However, this finding applies predominantly to stable adults aged 18 to 65 years with musculoskeletal pain. It demonstrated a comparable short-term efficacy and preliminary safety profile within a 60-minute observation window. However, given the small sample size and restrictive exclusion criteria of this study, further larger-scale trials are required to fully establish its safety profile, particularly in broader and higher-risk patient populations."Clinical trial number
TCTR20240624001. The Registration Date was 21 June2024.
Related
- Ciprofol-Based Total Intravenous Anesthesia During Pediatric Laparoscopic Surgery: A Double-Blind, Randomized Controlled, Non-Inferiority Clinical Trial
- Ultrasound guidance versus near-infrared light versus the standard technique for first-attempt success of peripheral intravenous catheterisation in adults with difficult venous access in a medical imaging department (RÉUSSIR-VVP): protocol for a single-centre, three arms, randomised controlled trial
- Non-Inferiority Margins in Randomized Controlled Trials in Abdominal Surgery- a Systematic Review
- Evaluation of percutaneous cryoneurotomy compared with surgical open neurotomy for the management of post-stroke spastic equinovarus foot in France: protocol for a multicentre, randomised controlled, open-label, non-inferiority trial
- Preoperative antibiotics for mild or moderate acute cholecystitis (POMMAC): study protocol for a non-inferiority, open-label, randomized controlled trial.
BibTeX
@article{preungprasob2026noninferiority,
title = {{A non-inferiority randomized controlled trial comparing nebulized fentanyl and intravenous morphine for acute pain management in the emergency department.}},
author = {Pitchapar Preungprasob and Rapeeporn Rojsaengroeng and Chirakit Hengrasmee and Pornsiri Kanokkarnjana and Yaowapa Changya},
journal = {BMC emergency medicine},
year = {2026},
month = jul,
doi = {10.1186/s12873-026-01679-5},
url = {https://europepmc.org/article/MED/42907741},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - A non-inferiority randomized controlled trial comparing nebulized fentanyl and intravenous morphine for acute pain management in the emergency department.
AU - Pitchapar Preungprasob
AU - Rapeeporn Rojsaengroeng
AU - Chirakit Hengrasmee
AU - Pornsiri Kanokkarnjana
AU - Yaowapa Changya
PY - 2026
DA - 2026/07/01
JO - BMC emergency medicine
DO - 10.1186/s12873-026-01679-5
UR - https://europepmc.org/article/MED/42907741
AB - Introduction Intravenous (IV) morphine is the standard treatment for acute pain in emergency department (ED), but is limited by invasiveness and adverse effects. Nebulized fentanyl is a noninvasive alternative. This study aimed to assess the efficacy of nebulized fentanyl compared with IV morphine for acute pain relief 15 min after administration. Secondary outcomes included pain score trends, adverse effects, and rescue analgesia requirements at 30, 45, and 60 min.Methods We conducted a double-blind, randomized controlled trial in patients aged 18 to 65 years who had severe pain (numeric rating scale(NRS) score ≥ 7) originating from headaches, musculoskeletal conditions, or cancer. Patients with abdominal pain, unstable vital signs, and chronic opioid use were excluded. Participants were randomly assigned to received either nebulized fentanyl (4 mcg/kg) or IV morphine (0.1 mg/kg). Pain scores, adverse events, and rescue analgesia were recorded at 15, 30, 45, and 60 min by emergency medicine residents who were blinded to treatment allocation. Non-inferiority margin was established if the upper limit of the 95% confidence interval (CI) for the mean NRS difference did not exceed 3 points.Results Seventy-two patients were enrolled, with comparable baseline characteristics and NRS scores (nebulized fentanyl: 7.94 ± 1.09; IV: 8.14 ± 0.90). Both groups showed significant pain reduction at 15 min (nebulized fentanyl: 5.56 ± 1.66; IV: 5.67 ± 1.85; p < 0.001), with no significant difference in mean NRS reduction (p = 0.83). At all measured time points (15, 30, 45, and 60 minutes), the upper limit of the 95% confidence interval (CI) for the mean difference in pain reduction remained below the predefined non-inferiority margin of 3.Conclusions Nebulized fentanyl is a non-inferior, non-invasive alternative to IV morphine for severe acute pain in the ED. However, this finding applies predominantly to stable adults aged 18 to 65 years with musculoskeletal pain. It demonstrated a comparable short-term efficacy and preliminary safety profile within a 60-minute observation window. However, given the small sample size and restrictive exclusion criteria of this study, further larger-scale trials are required to fully establish its safety profile, particularly in broader and higher-risk patient populations."Clinical trial number TCTR20240624001. The Registration Date was 21 June2024.
SN - 1471-227X
ER -